Can you have atherosclerosis without high cholesterol? Yes. Atherosclerosis can develop when LDL cholesterol is normal or even low, because plaque formation depends on endothelial injury, inflammation, and LDL retention in the artery wall, not on a single blood test. People with diabetes, hypertension, smoking exposure, chronic kidney disease, or inherited lipid disorders may build plaque while their standard LDL looks acceptable. High cholesterol remains a major accelerator, but it is neither necessary nor sufficient. The key issue is the number of atherogenic particles and the inflammatory response inside the arterial wall.
The Mechanism: Plaque Without a High LDL Number
Atherosclerosis is a chronic inflammatory disease of the arterial intima. It begins when apoB-containing lipoproteins enter the artery wall and bind to proteoglycans. That retention triggers oxidation, immune cell recruitment, and foam cell formation. The process can proceed even when the blood LDL-C level is unremarkable.
LDL-C measures cholesterol mass inside LDL particles, not the number of particles. Each LDL particle carries one apoB molecule, and particle size ranges roughly 20-25 nm. Two people can share an LDL-C of 100 mg/dL yet carry different apoB particle counts. Insulin resistance, diabetes, and high triglycerides often shift people toward more small dense LDL particles.
Endothelial injury is the second requirement. High blood pressure creates abnormal shear stress, smoking delivers oxidants, and hyperglycemia creates advanced glycation end products. Chronic kidney disease adds uremic toxins and calcium-phosphate stress. Each insult makes the endothelium more permeable to lipoproteins and more adhesive to immune cells.
In plain terms: cholesterol is the cargo, but the artery wall's response to retained particles drives the disease. A normal LDL-C does not guarantee a normal apoB burden or a quiet artery wall. This distinction explains why plaque can appear without a high cholesterol diagnosis.
Quantified Context: Can You Have Atherosclerosis Without High Cholesterol?
The JUPITER trial, published in 2008, tested this question directly. It enrolled 17,802 adults with LDL-C below 130 mg/dL and hs-CRP of 2 mg/L or higher. Rosuvastatin reduced major vascular events from 1.36 to 0.77 per 100 person-years, a 44% relative reduction. The trial enrolled people who would not have qualified for statins based on LDL alone.
Autopsy data show that plaque begins long before clinical cholesterol screening. The Pathobiological Determinants of Atherosclerosis in Youth study found advanced coronary lesions in about 2% of people aged 15-19 years. By ages 30-34 years, about 22% had advanced lesions. Many of those young people had lipid levels that would be called normal in adulthood.
Coronary artery calcium scanning adds another layer. A CAC score above 0 confirms that plaque is present, even when LDL-C is below 130 mg/dL. In the Multi-Ethnic Study of Atherosclerosis, CAC improved cardiovascular risk prediction beyond traditional risk factors. A CAC score of 0 is reassuring, but it does not erase the effect of diabetes, smoking, or inflammatory disease.
These data do not mean cholesterol is irrelevant. They mean the binary label of high cholesterol misses people whose risk comes from particle number, inflammation, or vascular injury. In plain terms: normal LDL-C is a useful number, but it is not a clean bill of arterial health.
Edge Cases: Who Is Missed by Standard Cholesterol
Diabetes is a major blind spot. Adults with type 2 diabetes have roughly two to four times the cardiovascular risk of adults without diabetes. Many have LDL-C near 100 mg/dL but elevated apoB, high triglycerides, and low HDL-C. The 2018 AHA/ACC cholesterol guideline treats diabetes as a risk enhancer that can justify statin therapy even when LDL-C is not high.
Chronic kidney disease is another edge case. An eGFR below 60 mL/min/1.73 m² raises cardiovascular risk through inflammation, mineral dysregulation, and hypertension. People with CKD stage 3-4 often die of cardiovascular causes before reaching dialysis. Their LDL-C may be normal or even low because malnutrition and inflammation lower cholesterol mass.
Lipoprotein(a) is a genetically determined particle that standard lipid panels miss. A level of 50 mg/dL or higher, or 125 nmol/L or higher, is considered elevated in many labs. Elevated Lp(a) is associated with roughly 1.4-1.6 times the risk of myocardial infarction per a 2009 JAMA meta-analysis. It can cause plaque in people whose LDL-C is otherwise acceptable.
Inflammatory diseases also matter. Rheumatoid arthritis, psoriasis, and systemic lupus erythematosus increase cardiovascular risk through systemic cytokines. Rheumatoid arthritis is associated with about 1.5-2 times the cardiovascular risk of the general population. Smoking and hypertension add independent injury, with smoking conferring roughly two to four times the risk of myocardial infarction.
These edge cases share a theme. The standard lipid panel measures cholesterol mass, while atherosclerosis responds to particle number and vascular inflammation. A person with diabetes, CKD, high Lp(a), or active inflammatory disease may need risk assessment beyond LDL-C. These edge cases are concrete examples of atherosclerosis without high cholesterol.
In plain terms: the question is not only how much cholesterol is in the blood, but how many atherogenic particles are hitting an inflamed artery wall.
Timeline of Plaque Formation and Detection
Atherosclerosis is a decades-long process. The timeline below shows when biological changes begin and when clinical detection usually occurs. Age ranges are approximate and vary by genetics, environment, and risk factors.
| Phase | Typical age window | What happens | Quantified marker |
|---|---|---|---|
| Initiation | 0-10 years | LDL and apoB particles enter the intima and bind proteoglycans | Fatty streaks can appear by age 10 |
| Fatty streak | 15-20 years | Foam cells accumulate and inflammatory signaling begins | About 2% have advanced coronary lesions at ages 15-19 |
| Fibrous plaque | 20-29 years | Smooth muscle cells form a cap over the lipid core | About 13% have advanced lesions at ages 25-29 |
| Calcification | 30-39 years | Calcium deposits form and CAC becomes detectable | About 22% have advanced lesions at ages 30-34 |
| Stenosis | 40-59 years | Plaque can narrow the lumen by more than 50% | Symptoms often absent until stenosis exceeds 70% |
| Rupture | 50-69 years | Thin-cap plaques rupture and trigger thrombosis | Most heart attacks arise from plaques under 70% stenosis |
| Advanced disease | 70+ years | Calcified, complex plaques and impaired flow | Clinical events rise sharply with age and comorbidity |
The table carries a practical lesson. A CAC score of 0 at age 45 does not guarantee a CAC score of 0 at age 65. The disease can be silent for decades while risk factors continue to injure the artery wall. In plain terms: atherosclerosis is a long exposure, not a single lab result.
Misconceptions and the Comparison Table
The most common misconception is that atherosclerosis equals high cholesterol. Cholesterol is causal, but the disease also requires retained particles, endothelial injury, and an inflammatory response. A person can have plaque with LDL-C of 90 mg/dL and no plaque with LDL-C of 160 mg/dL, depending on the rest of the risk profile.
A second misconception is that a normal total cholesterol rules out plaque. Total cholesterol mixes atherogenic and non-atherogenic particles. Non-HDL cholesterol and apoB track atherogenic particles more closely than total cholesterol. A third misconception is that high HDL-C cancels risk. Genetically raised HDL-C has not consistently reduced cardiovascular events in trials.
A fourth misconception is that statins are only for high LDL-C. The JUPITER trial showed benefit in people with LDL-C below 130 mg/dL and elevated hs-CRP. That does not mean everyone with normal LDL-C needs a statin. It means risk is broader than one lipid threshold.
For orientation, LDL-C 190 mg/dL is the severe hypercholesterolemia threshold, 160 mg/dL is high, 130 mg/dL is borderline-high, 100 mg/dL is near-optimal, and 70 mg/dL is a common very-high-risk target; these are risk-stratified action points rather than a single binary switch, and they sit alongside blood pressure 130/80 mm Hg and hs-CRP 1 and 3 mg/L cutoffs. The 2018 AHA/ACC cholesterol guideline uses risk estimates and risk enhancers, not one universal LDL target for everyone.
| Marker | Common threshold | What it captures | Quantified risk signal |
|---|---|---|---|
| LDL-C | 190 mg/dL or higher | Cholesterol mass in LDL particles | Severe hypercholesterolemia; familial hypercholesterolemia screening |
| Non-HDL-C | 30 mg/dL above LDL goal | All apoB-containing particles | Better risk prediction than LDL-C in diabetes |
| ApoB | 80-100 mg/dL in many labs | Particle number | Discordance with LDL-C signals hidden risk |
| Lp(a) | 50 mg/dL or 125 nmol/L | Genetically determined atherogenic particle | About 1.4-1.6 times myocardial infarction risk |
| hs-CRP | 2-3 mg/L or higher | Systemic inflammation | JUPITER enrolled 17,802 people with LDL below 130 mg/dL |
| CAC | Above 0, 100, or 300 | Calcified plaque burden | Higher scores track higher event risk |
| Blood pressure | 130/80 mm Hg or higher | Endothelial shear stress | Major independent risk factor |
| Diabetes | A1c 6.5% or higher | Hyperglycemia and particle changes | Roughly two to four times cardiovascular risk |
The table is not a treatment algorithm. It shows why a normal LDL-C can coexist with meaningful risk. In plain terms: the best single number depends on the person, and no single number tells the whole story.
What to Actually Do: Positive Actions and Red Flags
Start with a complete risk assessment rather than a single lipid value. Measure LDL-C, non-HDL-C, and apoB when available. Check Lp(a) once in adulthood, especially with premature cardiovascular disease or a family history. Add hs-CRP, fasting glucose or A1c, blood pressure, kidney function, and smoking status.
Use a validated risk calculator for primary prevention. The 2019 ACC/AHA primary prevention guideline supports CAC scoring for selected adults at intermediate risk. A CAC score of 0 can support deferring statins in some people, while a score of 100 or higher supports treatment. The score should be interpreted with age, diabetes, smoking, and family history.
Treat the artery wall, not just the lipid number. Aim for blood pressure below 130/80 mm Hg when tolerated. Aim for A1c below 7% in many adults with diabetes, individualized by age and comorbidity. Stop smoking completely and avoid secondhand smoke. Build 150 minutes per week of moderate aerobic activity and two muscle-strengthening sessions per week.
Use medication when overall risk justifies it. Statins remain the first-line therapy for most high-risk adults. Ezetimibe or PCSK9 inhibitors can be added when LDL-C remains above risk-specific goals. In very high-risk patients, an LDL-C goal of 70 mg/dL or lower is common, with some guidelines suggesting 55 mg/dL or lower for extreme risk. These goals are risk-stratified, not universal.
The actions above address atherosclerosis without high cholesterol, not only plaque linked to high LDL-C. Red-flag warnings require urgent medical attention:
- Chest pressure, squeezing, or heaviness lasting more than a few minutes, especially with sweating or nausea.
- Sudden shortness of breath, fainting, or palpitations with chest discomfort.
- New weakness or numbness on one side, facial droop, or difficulty speaking.
- Pain radiating to the jaw, neck, shoulder, or arm without a clear cause.
- Leg pain that occurs with walking and resolves with rest, especially in smokers or people with diabetes.
These symptoms can signal acute coronary syndrome, stroke, or peripheral artery disease. They are not proof of atherosclerosis, but they are reasons to seek care promptly. In plain terms: do not wait for a cholesterol test to act on warning symptoms.
Limitations of Current Evidence
The evidence that atherosclerosis can occur without high cholesterol is strong. The exact size of that risk in any individual remains harder to quantify. Lp(a) assays vary by 20-30% between methods, which complicates universal thresholds. hs-CRP can rise with infection or inflammation, so a single high value should be repeated before it drives a major decision.
CAC scanning involves a small radiation dose, roughly 1 mSv or less with modern protocols. It also detects calcified plaque better than non-calcified plaque, so a score of 0 can miss early soft plaque. Risk calculators are population tools and may underrepresent South Asian ancestry, inflammatory disease, CKD, and familial hypercholesterolemia.
Treatment trials mostly enrolled people with elevated LDL-C or elevated hs-CRP. It remains uncertain whether treating isolated high Lp(a) or isolated inflammation improves outcomes in everyone. The JUPITER trial supports a role for inflammation in people with normal LDL-C, but it does not prove that hs-CRP screening should be universal.
These limitations do not overturn the core answer. Atherosclerosis without high cholesterol is real, measurable, and biologically plausible. The practical task is to assess total atherogenic burden, vascular injury, and inflammation together. In plain terms: a normal cholesterol number is helpful information, not a guarantee of healthy arteries.